This clinical trial is for men and women with high-grade gliomas that has recurred for the first time. There is currently a need for more effective treatment methods for this disease.
The purpose of this study is to help answer the following research questions:
The study drug (LY3200882) will be administered orally (taken by mouth). You will receive a repeating cycle of either 14 days of treatment followed by 14 days with no treatment, or 21 days of treatment followed by 7 days with no treatment. You have a 1 in 2 chance of getting either the 2 week or 3 week treatment. Your treatment will stop when your disease progresses, you cannot tolerate the treatment, or you or your study doctor wishes to stop treatment.
The duration of your participation depends on how well your disease responds to the study treatment.